Revisiting the Roles of CAMP Signalling in the Progression of Prostate Cancer

Overview

Journal Biochem J

Specialty Biochemistry

Date 2023 Oct 13

PMID 37830741

Authors

Emma C Parsons

Ralf Hoffmann

George S Baillie

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is one of the most common cancers in men and one of the top causes of death in men worldwide. Development and function of both normal prostate cells and early-stage prostate cancer cells are dependent on the cross-talk between androgen signalling systems and a variety of other transduction pathways which drive differentiation of these cells towards castration-resistance. One such signalling pathway is the ubiquitous cAMP signalling axis which functions to activate spatially restricted pools of cAMP effectors such as protein kinase A (PKA). The importance of both PKA and cAMP in the development of prostate cancer, and their interactions with the androgen receptor, were the focus of a review by Merkle and Hoffmann in 2010. In this updated review, we revisit this topic with analysis of current PKA-related prostate cancer literature and introduce novel information on the relevance of another cAMP effector, the exchange protein directly activated by cAMP (EPAC).

Citing Articles

The Activation of the CCND1 Promoter by AP-1 and SOX Transcription Factors in PC3 Prostate Cancer Cells Can Be Prevented by Anacardic Acid Analogs.

Brunie M, Robichaud M, Touaibia M, Martin L Cell Biochem Biophys. 2024; .

PMID: 39729169 DOI: 10.1007/s12013-024-01646-6.

Biochemical pharmacology of adenylyl cyclases in cancer.

Jena B, Flaherty D, OBrien V, Watts V Biochem Pharmacol. 2024; 228:116160.

PMID: 38522554 PMC: 11410551. DOI: 10.1016/j.bcp.2024.116160.

Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma.

Zhang W, Zhang M, Sun M, Hu M, Yu M, Sun J Front Immunol. 2024; 14:1345734.

PMID: 38239355 PMC: 10794662. DOI: 10.3389/fimmu.2023.1345734.

References

Misra U, Pizzo S . Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem. 2011; 113(5):1488-500. DOI: 10.1002/jcb.24018. View

Sugawara K, Shibasaki T, Takahashi H, Seino S . Structure and functional roles of Epac2 (Rapgef4). Gene. 2015; 575(2 Pt 3):577-83. PMC: 6636354. DOI: 10.1016/j.gene.2015.09.029. View

Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P . Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007; 67(21):10455-65. DOI: 10.1158/0008-5472.CAN-07-2057. View

Sarwar M, Sandberg S, Abrahamsson P, Persson J . Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer. Urol Oncol. 2013; 32(1):25.e1-12. DOI: 10.1016/j.urolonc.2012.08.019. View

Dagar A, Kuzmis A, Rubinstein I, Sekosan M, Onyuksel H . VIP-targeted Cytotoxic Nanomedicine for Breast Cancer. Drug Deliv Transl Res. 2013; 2(6):454-62. PMC: 3546828. DOI: 10.1007/s13346-012-0107-x. View

Inda M, van Strijp D, den Biezen-Timmermans E, van Brussel A, Wrobel J, van Zon H . Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Eur Urol Focus. 2017; 4(3):376-384. DOI: 10.1016/j.euf.2017.05.010. View

Chung S, Furihata M, Tamura K, Uemura M, Daigo Y, Nasu Y . Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene. 2009; 28(32):2849-59. DOI: 10.1038/onc.2009.144. View

Cheng X, Ma Y, Moore M, Hemmings B, Taylor S . Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci U S A. 1998; 95(17):9849-54. PMC: 21425. DOI: 10.1073/pnas.95.17.9849. View

Koushyar S, Grant G, Uysal-Onganer P . The interaction of Wnt-11 and signalling cascades in prostate cancer. Tumour Biol. 2016; 37(10):13049-13057. DOI: 10.1007/s13277-016-5263-z. View

10.

Bos J . Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006; 31(12):680-6. DOI: 10.1016/j.tibs.2006.10.002. View

11.

Gulliver C, Huss S, Semjonow A, Baillie G, Hoffmann R . The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes. Cancers (Basel). 2023; 15(1). PMC: 9818961. DOI: 10.3390/cancers15010262. View

12.

Eder I, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A . Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo. Int J Mol Sci. 2013; 14(6):11942-62. PMC: 3709765. DOI: 10.3390/ijms140611942. View

13.

Leung J, Sadar M . Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Front Endocrinol (Lausanne). 2017; 8:2. PMC: 5239799. DOI: 10.3389/fendo.2017.00002. View

14.

Eder I, Culig Z, Ramoner R, Thurnher M, Putz T, Tiefenthaler M . Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 2000; 7(7):997-1007. DOI: 10.1038/sj.cgt.7700202. View

15.

Baillie G, Tejeda G, Kelly M . Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019; 18(10):770-796. PMC: 6773486. DOI: 10.1038/s41573-019-0033-4. View

16.

Takahashi M, Li Y, Dillon T, Stork P . Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP. J Biol Chem. 2016; 292(4):1449-1461. PMC: 5270487. DOI: 10.1074/jbc.M116.768986. View

17.

Taylor S, Zhang P, Steichen J, Keshwani M, Kornev A . PKA: lessons learned after twenty years. Biochim Biophys Acta. 2013; 1834(7):1271-8. PMC: 3763834. DOI: 10.1016/j.bbapap.2013.03.007. View

18.

Thiebaut C, Vlaeminck-Guillem V, Tredan O, Poulard C, Le Romancer M . Non-genomic signaling of steroid receptors in cancer. Mol Cell Endocrinol. 2021; 538:111453. DOI: 10.1016/j.mce.2021.111453. View

19.

Wong W, Scott J . AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol. 2004; 5(12):959-70. DOI: 10.1038/nrm1527. View

20.

Crocetti L, Floresta G, Cilibrizzi A, Giovannoni M . An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules. 2022; 27(15). PMC: 9370432. DOI: 10.3390/molecules27154964. View